Newsroom
Sorted by: Latest
-
TOURISE Unveils 2027 Summit Under the Theme “Alliances That Move the World”
RIYADH, Saudi Arabia--(BUSINESS WIRE)--Under the patronage of His Royal Highness Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, His Excellency Ahmed Al-Khateeb, Minister of Tourism and Chairman of TOURISE, today announced the TOURISE 2027 Summit, taking place in Riyadh from March 23-25, 2027. Building on the inaugural TOURISE Summit in November 2025 and a year of collaboration since, the 2027 edition will run under the theme “Alliances That Move the World.” Over thr...
-
Riassunto: Rubedo Life Sciences annuncia uno studio clinico per trattare la caduta dei capelli con il modulatore del GPX4 RLS-1496, la prima evidenza ex vivo sull'uomo che dimostra una solida crescita del follicolo pilifero
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo) oggi ha annunciato un nuovo studio clinico sull'RLS-1496 sperimentale in pazienti affetti da alopecia androgenetica (AGA), a partire dall'ottobre 2026, con i dati iniziali previsti per la prima metà del 2027. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua o...
-
Wells Fargo Bank Increases Prime Rate to 7.00 Percent
SAN FRANCISCO--(BUSINESS WIRE)--Wells Fargo Bank, N.A., said today it is increasing its prime rate to 7.00 percent from 6.75 percent, effective tomorrow, Sept. 17, 2026.About Wells FargoWells Fargo & Company (NYSE: WFC) is a leading financial services company that has approximately $2.3 trillion in assets. We provide a diversified set of banking, investment and mortgage products and services, as well as consumer and commercial finance, through our four reportable operating segments: Consumer...
-
Samenvatting: Rubedo Life Sciences kondigt klinische studie aan naar de behandeling van haarverlies met de GPX4-modulator RLS-1496; eerste ex vivo bewijs bij mensen toont krachtige haarfollikelgroei aan
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo) heeft vandaag een nieuwe klinische studie aangekondigd naar het onderzoeksmiddel RLS-1496 bij patiënten met androgenetische alopecia (AGA). De studie gaat van start in oktober 2026 en de eerste gegevens worden in de eerste helft van 2027 verwacht. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als...
-
SITE Centers Announces Sale of Shoppes at Paradise Pointe
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Shoppes at Paradise Pointe...
-
Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Doximity, Inc.
NEW YORK--(BUSINESS WIRE)--Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) filed a class action in the U.S. District Court for the Northern District of California alleging violations of the federal securities laws by Doximity, Inc. (“Doximity” or the “Company”) and certain of the Company’s current and former senior executives (collectively, “Defendants”). The action is brought on behalf of all investors who purchased or otherwise acquired Dox...
-
ASTS Investors Have Opportunity to Lead AST SpaceMobile, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES--(BUSINESS WIRE)--ASTS Investors Have Opportunity to Lead AST SpaceMobile, Inc. Securities Fraud Lawsuit with SBS Law...
-
شركة Rubedo Life Sciences تعلن عن دراسة سريرية لعلاج تساقط الشعر باستخدام مُعدِّل GPX4، وهو عقار RLS-1496، وتُظهر أول أدلة بشرية خارج الجسم أنه يحفّز نموًا قويًا لبصيلات الشعر
ماونتن فيو، كاليفورنيا--(BUSINESS WIRE)--أعلنت اليوم شركة Rubedo Life Sciences, Inc. (Rubedo) عن دراسة سريرية جديدة للعقار التجريبي RLS-1496 على مرضى الثعلبة الأندروجينية (AGA)، ومن المقرر أن تبدأ في أكتوبر 2026، مع توقع صدور البيانات الأولية في النصف الأول من عام 2027. تمثّل هذه الدراسة أول تقييم سريري على الإطلاق لمُعدِّل GPX4 لعلاج تساقط الشعر، وتوسّع نطاق البرنامج الذي أثبت أنَّ RLS-1496 هو أول مُعدِّل لإنزيم GPX4 في العالم يدخل تجارب سريرية على البشر من أي نوع.يتناول هذا البيان الصحفي الوسا...
-
Investor Notice: Robbins LLP Informs Investors of the Doximity, Inc. Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Doximity, Inc. (NYSE: DOCS) common stock August 8, 2024 and May 13, 2026, inclusive (the Class Period). Doximity is a digital platform for medical professionals that combines health care news, workflow products, and clinician networking.The complaint alleges that Doximity failed to disclose to investors it was lo...
-
Ares and PSP Investments Establish Joint Venture to Invest Up to $2.4 Billion in U.S. Logistics Real Estate
NEW YORK & MONTRÉAL--(BUSINESS WIRE)--Ares Management Corporation (NYSE: ARES), a leading global alternative investment manager, and the Public Sector Pension Investment Board (“PSP Investments”), one of Canada’s largest pension investors, announced today that an Ares Real Estate fund (“Ares”) and PSP Investments have established a new joint venture to invest up to $2.4 billion in logistics real estate opportunities in the U.S. The joint venture combines Ares Real Estate’s vertically integrated...